Loading...
XSHE000710
Market cap394mUSD
Jan 09, Last price  
8.22CNY
1D
-0.12%
1Q
-3.53%
Jan 2017
-82.73%
Name

Berry Genomics Co Ltd

Chart & Performance

D1W1MN
XSHE:000710 chart
P/E
—
P/S
2.52
EPS
—
Div Yield, %
0.53%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-4.37%
Revenues
1.15b
-15.83%
119,662,111130,579,949148,658,025180,608,401286,852,054408,956,180464,161,241409,661,686331,077,628262,234,824273,643,289230,056,809247,380,2521,171,191,3411,439,789,0441,617,641,3011,540,385,7321,422,180,9211,368,007,2111,151,416,785
Net income
-427m
638,03601,192,93802,818,75210,453,3308,076,488500,761392,98406,878,24800232,749,588268,091,948390,618,298210,665,18800-427,196,505
CFO
111m
+424.14%
07,580,39811,677,9754,703,24857,755,051076,193,688048,265,43215,627,95518,909,9200074,350,103165,331,569123,056,710161,310,07594,031,45221,178,809111,006,913
Dividend
May 25, 20010.15 CNY/sh
Earnings
May 16, 2025

Profile

Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.
URL
https://www.berrygenomics.com/
IPO date
Apr 22, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,151,417
-15.83%
1,368,007
-3.81%
Cost of revenue
979,895
1,217,591
Unusual Expense (Income)
NOPBT
171,522
150,417
NOPBT Margin
14.90%
11.00%
Operating Taxes
(28,159)
Tax Rate
NOPAT
199,681
150,417
Net income
(427,197)
 
Dividends
(15,496)
Dividend yield
0.38%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
202,637
216,690
Long-term debt
49,190
136,369
Deferred revenue
11,020
12,074
Other long-term liabilities
1
Net debt
(134,771)
(118,761)
Cash flow
Cash from operating activities
111,007
21,179
CAPEX
(55,102)
Cash from investing activities
(47,371)
Cash from financing activities
(67,286)
FCF
691,956
195,841
Balance
Cash
352,008
338,069
Long term investments
34,590
133,751
Excess cash
329,028
403,419
Stockholders' equity
657,560
1,552,278
Invested Capital
1,824,917
2,270,391
ROIC
9.75%
6.62%
ROCE
7.87%
5.58%
EV
Common stock shares outstanding
353,055
353,521
Price
11.52
0.96%
11.41
-41.19%
Market cap
4,067,193
0.83%
4,033,680
-41.19%
EV
3,962,988
3,942,860
EBITDA
285,460
253,139
EV/EBITDA
13.88
15.58
Interest
16,621
17,635
Interest/NOPBT
9.69%
11.72%